These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32256058)

  • 1. The Effect of Cytoreductive Partial Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma.
    Chen J; He Q; Liu W; Li Y; Zhuang W
    Clin Interv Aging; 2020; 15():431-439. PubMed ID: 32256058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cytoreductive Partial Nephrectomy versus Cytoreductive Radical Nephrectomy for Locally T
    Xiong SC; Shao YX; Hu X; Yang WX; Dou WC; Li X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 Jul; 51(4):546-551. PubMed ID: 32691565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma.
    Lenis AT; Salmasi AH; Donin NM; Faiena I; Johnson DC; Drakaki A; Gollapudi K; Blumberg J; Belldegrun AS; Pantuck AJ; Chamie K
    Urol Oncol; 2018 Feb; 36(2):78.e21-78.e28. PubMed ID: 29128421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Population Study to Identify Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Sarcomatoid Renal Cell Carcinoma from the Surveillance, Epidemiology, and End Results (SEER) Database.
    Ji B; Li D; Fu S; Zhang Z; Yang T; Wu Y; Zuo Y; Xu Z; Yu N
    Med Sci Monit; 2020 Jun; 26():e921297. PubMed ID: 32516796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic renal cell carcinoma patients of T4 stage who are in status of N1 stage or older than 76 years cannot benefit from cytoreductive nephrectomy.
    Zhang Z; Wu H; Yang T; Wu Y; Yu N; Xu Z
    BMC Cancer; 2020 Sep; 20(1):844. PubMed ID: 32883242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreductive partial and radical nephrectomies provide equivalent oncologic outcomes in T1-2M1 renal cell carcinoma.
    Tian J; Zeng X; Zhu J; Guan W; Hu Z; Yang C
    Transl Cancer Res; 2023 Feb; 12(2):301-309. PubMed ID: 36915574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy.
    Daugherty M; Daugherty E; Jacob J; Shapiro O; Mollapour M; Bratslavsky G
    Urol Oncol; 2019 Mar; 37(3):182.e9-182.e15. PubMed ID: 30528396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy.
    DiNatale RG; Xie W; Becerra MF; Silagy AW; Attalla K; Sanchez A; Mano R; Marcon J; Blum KA; Benfante NE; Voss MH; Motzer RJ; Coleman J; Choueiri TK; Reznik E; Russo P; Heng DYC; Hakimi AA
    Eur Urol Oncol; 2020 Feb; 3(1):47-56. PubMed ID: 31735646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of cytoreductive partial versus radical nephrectomy in metastatic renal cell carcinoma: To be on the horns of a dilemma.
    Shemshaki H; Al-Mamari SA; Al-Hooti Q; Geelani IA; Al Salmi I; Narayana Kurukkal S; Kumar S; Al Julandani A; Sadeghzadeh S
    Urologia; 2022 May; 89(2):160-166. PubMed ID: 35422178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
    You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
    Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Nomogram Model to Identify Appropriate Candidates from Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Based on the Surveillance, Epidemiology and End Results Database.
    Ren K; Ning H; Wu HH; Wu F; Lyu JJ
    Clin Genitourin Cancer; 2024 Jun; 22(3):102062. PubMed ID: 38548487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of cytoreductive nephrectomy in renal cell carcinoma patients with liver metastasis.
    Guo B; Liu S; Wang M; Hou H; Liu M
    Bosn J Basic Med Sci; 2021 Apr; 21(2):229-234. PubMed ID: 32767963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm.
    Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Parodi S; Dell'Oglio P; Palumbo C; Briganti A; De Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
    Eur Urol Focus; 2023 Sep; 9(5):742-750. PubMed ID: 36906483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.
    Jiang W; Shou J; Shi H; Wen L; Zhang H; Zheng S; Li C; Ma J
    Technol Cancer Res Treat; 2021; 20():15330338211019507. PubMed ID: 34032149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis.
    Xiao WJ; Zhu Y; Dai B; Zhang HL; Ye DW
    Int Braz J Urol; 2015; 41(2):288-95. PubMed ID: 26005970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.
    Faiena I; Salmasi A; Lenis AT; Donin NM; Johnson DC; Bachour K; Drakaki A; Belldegrun AS; Pantuck AJ; Chamie K
    Urol Oncol; 2018 Feb; 36(2):79.e19-79.e26. PubMed ID: 29103965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a role for partial nephrectomy in patients with metastatic renal cell carcinoma?
    Hellenthal NJ; Mansour AM; Hayn MH; Schwaab T
    Urol Oncol; 2013 Jan; 31(1):36-41. PubMed ID: 21396834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do renal cell carcinoma patients with brain metastases still need nephrectomy?
    Zhuang W; Li Y; Chen P; Wang J; Liu W; Chen J
    Int Urol Nephrol; 2019 Jun; 51(6):941-949. PubMed ID: 30953259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive surgical margin following radical nephrectomy is an independent predictor of local recurrence and disease-specific survival.
    Abu-Ghanem Y; Ramon J; Berger R; Kaver I; Fridman E; Leibowitz-Amit R; Dotan ZA
    World J Surg Oncol; 2017 Nov; 15(1):193. PubMed ID: 29096642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.